InvestorsHub Logo
Followers 64
Posts 5750
Boards Moderated 0
Alias Born 07/09/2003

Re: None

Wednesday, 08/24/2016 4:14:17 PM

Wednesday, August 24, 2016 4:14:17 PM

Post# of 859
Lots of deals with customers, but so much of BLFS's success depends on the success of its customers. Many are still just in the trial stage.

Mike Rice, BioLife President & CEO, remarked, "Kolon's BLA submission seeking approval to market Invossa in Korea is encouraging news for millions of patients suffering from osteoarthritis. We are very pleased that TissueGene and Kolon have selected CryoStor as the best in class biopreservation media for commercializing Invossa. CryoStor and HypoThermosol®, our cell and tissue storage and shipping media, are now incorporated into more than 220 pre-clinical validations and clinical trials of cell-based therapies, targeting blood cancers, solid tumors, vision loss, heart disease, stroke, and movement disorders such as osteoarthritis. We look forward to progress by Kolon and other customers in gaining regulatory approvals to commence commercial manufacturing of these life-changing and life-saving cell therapies."



http://finance.yahoo.com/news/biolife-solutions-cryostor-integrated-kolon-100000090.html

techisbest

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLFS News